DK3655395T3 - Fremgangsmåde til fremstilling af n-((1r,2s,sr)-5-(tert-butylamino)-2-((s)-3-(7- tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1- yl)cyclohexyl)acetamid - Google Patents
Fremgangsmåde til fremstilling af n-((1r,2s,sr)-5-(tert-butylamino)-2-((s)-3-(7- tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1- yl)cyclohexyl)acetamid Download PDFInfo
- Publication number
- DK3655395T3 DK3655395T3 DK18785785.9T DK18785785T DK3655395T3 DK 3655395 T3 DK3655395 T3 DK 3655395T3 DK 18785785 T DK18785785 T DK 18785785T DK 3655395 T3 DK3655395 T3 DK 3655395T3
- Authority
- DK
- Denmark
- Prior art keywords
- tert
- butylpyrazolo
- acetamid
- oxopyrrolidin
- triazin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/22—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762534908P | 2017-07-20 | 2017-07-20 | |
| PCT/US2018/042797 WO2019018592A2 (en) | 2017-07-20 | 2018-07-19 | PROCESS FOR THE PREPARATION OF N- ((1R, 2S, 5R) -5- (TERT-BUTYLAMINO) -2 - ((S) -3- (7-TERT-BUTYLPYRAZOLO [1,5-A]] 1,3 , 5] triazin-4-ylamino) -2-oxopyrrolidin-1-yl) cyclohexyl) acetamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3655395T3 true DK3655395T3 (da) | 2022-03-07 |
Family
ID=63834628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18785785.9T DK3655395T3 (da) | 2017-07-20 | 2018-07-19 | Fremgangsmåde til fremstilling af n-((1r,2s,sr)-5-(tert-butylamino)-2-((s)-3-(7- tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1- yl)cyclohexyl)acetamid |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11254679B2 (da) |
| EP (1) | EP3655395B1 (da) |
| JP (1) | JP2020527576A (da) |
| KR (1) | KR20200031656A (da) |
| CN (1) | CN110933946A (da) |
| AU (1) | AU2018304290B2 (da) |
| BR (1) | BR112020000418A2 (da) |
| CA (1) | CA3070423A1 (da) |
| CY (1) | CY1125023T1 (da) |
| DK (1) | DK3655395T3 (da) |
| EA (1) | EA202090346A1 (da) |
| ES (1) | ES2907640T3 (da) |
| HR (1) | HRP20220264T8 (da) |
| HU (1) | HUE058049T2 (da) |
| IL (2) | IL293088A (da) |
| LT (1) | LT3655395T (da) |
| PL (1) | PL3655395T3 (da) |
| PT (1) | PT3655395T (da) |
| RS (1) | RS62941B1 (da) |
| SG (1) | SG11202000441QA (da) |
| SI (1) | SI3655395T1 (da) |
| WO (1) | WO2019018592A2 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020014574A2 (pt) * | 2018-01-22 | 2020-12-08 | Bristol-Myers Squibb Company | Composições e métodos para o tratamento do câncer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4546923B2 (ja) * | 2003-05-30 | 2010-09-22 | チョンウェ ファーマ コーポレーション | ベータストランドミメティックスおよびこれに関連した方法 |
| US7671062B2 (en) * | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
| US7629351B2 (en) * | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
| CN100593536C (zh) * | 2007-01-09 | 2010-03-10 | 吉尔生化（上海）有限公司 | 一种n-芴甲氧羰基-n-三苯甲基-d-谷氨酰胺的合成法 |
| US8383812B2 (en) * | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| TWI640541B (zh) * | 2011-12-28 | 2018-11-11 | 中外製藥股份有限公司 | Peptide compound having an annular portion and pharmaceutical composition thereof |
-
2018
- 2018-07-19 CA CA3070423A patent/CA3070423A1/en active Pending
- 2018-07-19 SI SI201830566T patent/SI3655395T1/sl unknown
- 2018-07-19 LT LTEPPCT/US2018/042797T patent/LT3655395T/lt unknown
- 2018-07-19 PL PL18785785T patent/PL3655395T3/pl unknown
- 2018-07-19 WO PCT/US2018/042797 patent/WO2019018592A2/en unknown
- 2018-07-19 HU HUE18785785A patent/HUE058049T2/hu unknown
- 2018-07-19 US US16/631,915 patent/US11254679B2/en active Active
- 2018-07-19 SG SG11202000441QA patent/SG11202000441QA/en unknown
- 2018-07-19 DK DK18785785.9T patent/DK3655395T3/da active
- 2018-07-19 IL IL293088A patent/IL293088A/en unknown
- 2018-07-19 KR KR1020207004510A patent/KR20200031656A/ko active IP Right Grant
- 2018-07-19 CN CN201880046394.0A patent/CN110933946A/zh active Pending
- 2018-07-19 ES ES18785785T patent/ES2907640T3/es active Active
- 2018-07-19 RS RS20220175A patent/RS62941B1/sr unknown
- 2018-07-19 EP EP18785785.9A patent/EP3655395B1/en active Active
- 2018-07-19 PT PT187857859T patent/PT3655395T/pt unknown
- 2018-07-19 JP JP2020502357A patent/JP2020527576A/ja active Pending
- 2018-07-19 AU AU2018304290A patent/AU2018304290B2/en not_active Ceased
- 2018-07-19 EA EA202090346A patent/EA202090346A1/ru unknown
- 2018-07-19 BR BR112020000418-9A patent/BR112020000418A2/pt active Search and Examination
- 2018-07-19 HR HRP20220264TT patent/HRP20220264T8/hr unknown
-
2020
- 2020-01-14 IL IL272034A patent/IL272034B/en unknown
-
2022
- 2022-02-22 US US17/677,312 patent/US20220177482A1/en not_active Abandoned
- 2022-02-23 CY CY20221100161T patent/CY1125023T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3655395T1 (sl) | 2022-04-29 |
| US20220177482A1 (en) | 2022-06-09 |
| AU2018304290A1 (en) | 2020-03-05 |
| RS62941B1 (sr) | 2022-03-31 |
| IL293088A (en) | 2022-07-01 |
| AU2018304290A8 (en) | 2020-04-02 |
| PT3655395T (pt) | 2022-02-22 |
| EP3655395B1 (en) | 2021-12-01 |
| BR112020000418A2 (pt) | 2020-07-14 |
| WO2019018592A3 (en) | 2019-02-28 |
| US20200223852A1 (en) | 2020-07-16 |
| LT3655395T (lt) | 2022-03-10 |
| IL272034B (en) | 2022-06-01 |
| HRP20220264T1 (hr) | 2022-05-13 |
| CA3070423A1 (en) | 2019-01-24 |
| PL3655395T3 (pl) | 2022-03-07 |
| US11254679B2 (en) | 2022-02-22 |
| CY1125023T1 (el) | 2023-03-24 |
| ES2907640T3 (es) | 2022-04-25 |
| IL272034A (en) | 2020-03-31 |
| KR20200031656A (ko) | 2020-03-24 |
| HUE058049T2 (hu) | 2022-06-28 |
| WO2019018592A2 (en) | 2019-01-24 |
| CN110933946A (zh) | 2020-03-27 |
| SG11202000441QA (en) | 2020-02-27 |
| JP2020527576A (ja) | 2020-09-10 |
| AU2018304290B2 (en) | 2022-11-17 |
| EA202090346A1 (ru) | 2020-08-18 |
| HRP20220264T8 (hr) | 2022-05-27 |
| EP3655395A2 (en) | 2020-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3458456T3 (da) | Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid | |
| DK3775091T3 (da) | Stabiliserede fluorolefinsammensætninger og fremgangsmåder til fremstilling, oplagring og anvendelse deraf | |
| WO2018042343A3 (en) | Compounds that inhibit 3c and 3cl proteases and methods of use thereof | |
| EP3539963A4 (en) | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| MX2020011478A (es) | Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos. | |
| EP3233809A4 (en) | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide | |
| EP3284738A4 (en) | 5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition, and use thereof | |
| EP3626718A4 (en) | FIVE- AND SIX-MEMBER AZA-AROMATIC COMPOUND, MANUFACTURING METHOD FOR IT, PHARMACEUTICAL COMPOSITION AND APPLICATION | |
| DK3286176T3 (da) | Krystallinske former af 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleat | |
| PH12016501472B1 (en) | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use | |
| EA201892235A1 (ru) | Гранулированная композиция для перорального применения | |
| EA202091337A1 (ru) | Ингибиторы гистонацетилтрансфераз семейства myst | |
| IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
| DK3259255T3 (da) | (2r,4r)-5-(5'-chlor-2'-fluorbiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazol-2-carbonyl)amino]pentansyre | |
| EP3687551A4 (en) | FLUORUSUBSTITUTED PORPHYRINE COMPOUNDS, THESE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR MANUFACTURE AND USE | |
| EP3856174A4 (en) | HDAC1, 2 INHIBITORS | |
| DK3655395T3 (da) | Fremgangsmåde til fremstilling af n-((1r,2s,sr)-5-(tert-butylamino)-2-((s)-3-(7- tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1- yl)cyclohexyl)acetamid | |
| EA201691741A1 (ru) | Фармацевтическая композиция | |
| DK3923914T3 (da) | Afabicin-formulering, fremgangsmåde til fremstilling deraf | |
| EP3725804A4 (en) | ANTI-BMP10 ANTIBODY AND THERAPEUTIC AGENT FOR HIGH BLOOD PRESSURE AND HIGH PRESSURE DISEASES, CONTAINING THE ANTIBODY AS AN ACTIVE SUBSTANCE | |
| EA201891848A1 (ru) | Фармацевтическая композиция для применения в лечении фиброза | |
| DK3164385T3 (da) | Ny polymorf form af n-[2-(6-fluor-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluorpropoxy)benzylaminhydrochlorid for behandlingen af alzheimers | |
| EA201692217A1 (ru) | Полиморфные формы фуразидина | |
| WO2017085677A3 (en) | Hiv maturation inhibitor formulations |